Bart Staels, PhD., is director of the Inserm Unit UMR1011 with laboratories at the Lille Pasteur Institute and
Medical Faculty campus.
After his doctorate at the University of Leuven, Belgium, he completed his training at the UCSF, San Francisco and
RPR, Paris. He is Senior Member of the Institut Universitaire de France, co-founder and board member of
the European Genomic Institute for Diabetes (EGID, Lille), member of the French National Academy of
Pharmacy and the Belgian Royal Academy of Medicine, and past-president of the French Atherosclerosis
Society.
Awards: the EAS Young Investigator Award, the CNRS Bronze Medal, the Lifetime Achievement Award of
the British Atherosclerosis Society, the “Barré” prize from the Faculté de Pharmacie of Montreal (2007), the
“JP Binet” prize from the Fondation pour la Recherche Médicale (2011), the “Distinguished Leader in
Insulin Resistance” award (2012) and the ICBL Laurens van Deenen award (2017).
Professor Staels’ research covers the fields of obesity, diabetes, hepatic and cardiovascular diseases focussing on
molecular pharmacology of these cardio-metabolic diseases. He particularly studies the role of nuclear
receptors in the control of inflammation and lipid and glucose homeostasis as well as the transcriptional
mechanisms involved.
Bart Staels has published >900 articles, abstracts and book chapters. He received the ISI citations award, ranked
in the 2018 and 2022 Highly Cited Researchers list of Clarivate Analytics; and the Google Scholar h-index
2019 list. In 2022, he was ranked #1 in France in the Top 1000 Scientists in the field of Medicine by
Research.com
